AI model aims to personalize liver cancer therapy
NCT ID NCT07584317
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests an artificial intelligence (AI) model that analyzes medical images and other data to predict how well liver cancer patients will respond to a combination of treatments: TACE (a procedure that blocks blood flow to the tumor), immunotherapy, and targeted therapy. The goal is to see if the AI can accurately identify which patients benefit most, helping doctors tailor treatment. About 1,170 adults with hepatocellular carcinoma will participate, and the study focuses on improving prediction rather than testing a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.